Evidence map›Paper›PMID 31647839›Full record

ArticlePloS one2019

Temporal trends in breast cancer survival by race and ethnicity: A population-based cohort study.

Deirdre A Hill, Eric R Prossnitz, Melanie Royce, Andrea Nibbe

Registry-linked trialAbstract read
In one paragraph

Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05850637 (Phase II Study to Evaluate the Effectiveness and Toxicity of Adjuvant Ultra-hypofractionated Radiotherapy for the Treatment of Early and Locally Advanced Breast Cancer), which is not on this map. Cited by 16 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05850637 phase2completednot on this map

Phase II Study to Evaluate the Effectiveness and Toxicity of Adjuvant Ultra-hypofractionated Radiotherapy for the Treatment of Early and Locally Advanced Breast Cancer

TypeinterventionalSponsorPrevent Senior InstituteRan2019 to 2023Enrolled60ConditionsBreast Cancer FemaleArmsadjuvant ultra-hypofractionated radiotherapy
3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. PI3 K/AKT/mTOR pathway and its role in breast cancer stem cells.Naunyn-Schmiedeberg's archives of pharmacology · 2025
    Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Deirdre A HillDepartment of Internal Medicine, University of New Mexico, Albuquerque, New Mexico, United States of America.ORCID 0000-0002-8495-659X
Eric R ProssnitzDepartment of Molecular Medicine, University of New Mexico, Albuquerque, New Mexico, United States of America.ORCID 0000-0001-9190-8302
Melanie RoyceDepartment of Internal Medicine, University of New Mexico, Albuquerque, New Mexico, United States of America.ORCID 0000-0002-7173-1295
Andrea NibbeDepartment of Internal Medicine, University of New Mexico, Albuquerque, New Mexico, United States of America.

Funding

WOMEN'S CANCERS RESEARCH PROGRAMP30CA118100 · NCI · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI Yolanda Sanchez · 2005 to 2026
$57.1M
Molecular Mechanisms and Applications of Novel ER/GPER-selective LigandsR01CA194496 · NCI · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI ARTERBURN, JEFFREY B, PROSSNITZ, ERIC R · 2016 to 2025
$4.1M
G protein-coupled estrogen receptor GPER and breast carcinogenesisR01CA163890 · NCI · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI PROSSNITZ, ERIC R · 2012 to 2023
$3.3M
Towards a Transdisciplinary Understanding of Breast Cancer Survival DisparitiesR01CA132877 · NCI · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI HILL, DEIRDRE · 2010 to 2014
$2.6M
NCI NIH HHS P30 CA118100NCI NIH HHS R01 CA132877NCI NIH HHS R01 CA163890NCI NIH HHS R01 CA194496
6 · The paper itself

Abstract

introductionDifferences in breast cancer survival by race and ethnicity are often assumed to be a fairly recent phenomenon, and are hypothesized to have arisen due to gaps in receipt of screening or therapy. The emergence of these differences in calendar time have implications for identification of their origin. We sought to determine whether breast cancer survival differences by race or ethnicity arose in tandem with the advent of screening or therapeutic advances. MATERIALS AND

methodsA cohort of women diagnosed with invasive breast cancer from 1975-2009 in 18 population-based registries were followed for five-year breast cancer cause-specific survival. Differences in survival according to race/ethnicity and estrogen receptor status were quantified in Cox proportional hazards models, with estimation of hazard ratios (HR), 95% confidence intervals (CI), and absolute risk differences. For 2010, we also assessed differences in survival by breast cancer subtypes defined by hormone receptor and Her2/neu status.

resultsAmong over 930,000 women, initial differences in five-year breast cancer-specific survival by race became apparent among 1975-1979 diagnoses and continued to be evident, with stronger disparities apparent in those of Black vs. White Non-Hispanic (WNH) race and among estrogen-receptor positive vs. negative disease. Within breast cancer subtype, all included race/ethnic groups experienced disparate survival in comparison with WNH women for triple-negative disease. Black women had a consistent gap in absolute survival of .10-.12, compared with WNH women, from 1975-1979 through all included time periods, such that 5- year survival of Black women diagnosed in 2005-09 lagged more than 20 years behind that of WNH women. DISCUSSION: Survival differed by race for diagnoses that predate the introduction of mammographic screening and most therapeutic advances. Absolute differences in survival by race and ethnicity have remained almost constant over 40 years of observation, suggesting early origins for some contributors.

Indexed as

AdultAgedAged, 80 and overBreast NeoplasmsEthnicityFemaleHumansMiddle AgedMortalityPrognosisRacial GroupsRetrospective StudiesSurvival Rate

Identifiers

PMID31647839
PMCPMC6812853

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.